BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
DTSTART;VALUE=DATE:20250101
TZNAME:UTC
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Date: Tuesday 12th April 2022\nTime: 14:00-15:00 BST | 15:00-16
 :00 CEST\nSpeaker:&nbsp\;Tim Holland-Letz\n\nWho is this event intended fo
 r?&nbsp\;Statisticians in Pharma.\nWhat is the benefit of attending?&nbsp\
 ;The chance to learn about new study designs.\nRegistration\nYou can now r
 egister for this event. Registration fees are as follows:\n-&nbsp\;Members
  of PSI&nbsp\;= Free of charge\n-&nbsp\;Non-Members of PSI&nbsp\;= Free of
  charge\nTo register for the session\, please&nbsp\;click here.\nOverview\
 nIn practical dose response trials\, especially in a cell culture context\
 , experimental designs to establish functional relationships between dose 
 and effect of a substance are generally chosen based on simple rules of th
 umb. These designs are generally reasonably effective\, but not optimal.\n
 \nIn this webinar we give an overview over the statistical optimal design 
 approach in this context. We show how optimal designs can be constructed\,
  covering mainly all-purpose designs (D-optimality) but also more specific
  designs (c-optimality). We introduce a graphical representation. Next\, w
 e show how these concepts can be extended to trials aiming to estimate the
  interaction between two different substances given simultaneously.\n\nFin
 ally\, we present an R-Shiny application which allows construction of opti
 mal designs in most of these contexts with a minimum of theoretical knowle
 dge.&nbsp\;\nSpeaker details\n\n\n\n    \n        \n            \n        
     Speaker\n            \n            \n            Biography\n          
   \n        \n        \n            \n            Tim Holland-Letz\n      
       \n            \n            Tim Holland-Letz studied Statistics at t
 he Technical University of Dortmund. In 2010\, he completed his PhD in the
  same subject in cooperation with the Department of Mathematics of the Ruh
 r-University Bochum\, focusing on the topic of optimal experimental design
 . At the same time he was employed at the Department of Medical Informatic
 s and Biometry also at the Ruhr-University\, working mainly on clinical st
 udies and general applied statistics in medical research. In 2011\, he mov
 ed to the Biostatistics Division within the Deutsches Krebsforschungszentr
 um (DKFZ) in Heidelberg. From this moment on\, he has concentrated more on
  preclinical studies\, with a special focus on optimal experimental design
 s and dose-response analysis. However\, he still works on more or less all
  kinds of statistical problems arising in research and preclinical studies
 . In 2019 he completed his Habilitation in Medical Biostatistics at the Un
 iversity of Heidelberg. \n            \n        \n    \n\n&nbsp\;
DTEND:20220412T140000Z
DTSTAMP:20260807T183119Z
DTSTART:20220412T130000Z
LOCATION:
SEQUENCE:0
SUMMARY:PSI Pre-Clinical SIG Webinar: Optimal experimental design in precli
 nical dose-response studies
UID:RFCALITEM639217242790890355
X-ALT-DESC;FMTTYPE=text/html:<strong>Date</strong>: Tuesday 12th April 2022
 <br />\n<strong>Time</strong>: 14:00-15:00 BST | 15:00-16:00 CEST<br />\n<
 strong>Speaker</strong>:&nbsp\;Tim Holland-Letz<br />\n<br />\nWho is this
  event intended for?&nbsp\;Statisticians in Pharma.<br />\nWhat is the ben
 efit of attending?&nbsp\;The chance to learn about new study designs.<br /
 >\n<h4>Registration</h4>\n<p>You can now register for this event. Registra
 tion fees are as follows:<br />\n-&nbsp\;Members of PSI&nbsp\;= Free of ch
 arge<br />\n-&nbsp\;Non-Members of PSI&nbsp\;= Free of charge<br />\nTo re
 gister for the session\, please&nbsp\;<strong><a href="https://psi.glueup.
 com/event/52038/" target="_blank">click here</a></strong>.</p>\n<h4>Overvi
 ew</h4>\n<p>In practical dose response trials\, especially in a cell cultu
 re context\, experimental designs to establish functional relationships be
 tween dose and effect of a substance are generally chosen based on simple 
 rules of thumb. These designs are generally reasonably effective\, but not
  optimal.<br />\n<br />\nIn this webinar we give an overview over the stat
 istical optimal design approach in this context. We show how optimal desig
 ns can be constructed\, covering mainly all-purpose designs (D-optimality)
  but also more specific designs (c-optimality). We introduce a graphical r
 epresentation. Next\, we show how these concepts can be extended to trials
  aiming to estimate the interaction between two different substances given
  simultaneously.<br />\n<br />\nFinally\, we present an R-Shiny applicatio
 n which allows construction of optimal designs in most of these contexts w
 ith a minimum of theoretical knowledge.&nbsp\;</p>\n<h4>Speaker details</h
 4>\n<table border="1" cellspacing="0" cellpadding="0" width="652">\n</tabl
 e>\n<table class="table table-striped table-bordered">\n    <tbody>\n     
    <tr>\n            <td valign="top" style="width: 132px\;">\n           
  <p><strong>Speaker</strong></p>\n            </td>\n            <td valig
 n="top" style="width: 520px\;">\n            <p><strong>Biography</strong>
 </p>\n            </td>\n        </tr>\n        <tr>\n            <td vali
 gn="top" style="width: 132px\;">\n            <p>Tim Holland-Letz</p>\n   
          </td>\n            <td valign="top" style="width: 520px\;">\n    
         <p>Tim Holland-Letz studied Statistics at the Technical University
  of Dortmund. In 2010\, he completed his PhD in the same subject in cooper
 ation with the Department of Mathematics of the Ruhr-University Bochum\, f
 ocusing on the topic of optimal experimental design. At the same time he w
 as employed at the Department of Medical Informatics and Biometry also at 
 the Ruhr-University\, working mainly on clinical studies and general appli
 ed statistics in medical research. In 2011\, he moved to the Biostatistics
  Division within the Deutsches Krebsforschungszentrum (DKFZ) in Heidelberg
 . From this moment on\, he has concentrated more on preclinical studies\, 
 with a special focus on optimal experimental designs and dose-response ana
 lysis. However\, he still works on more or less all kinds of statistical p
 roblems arising in research and preclinical studies. In 2019 he completed 
 his Habilitation in Medical Biostatistics at the University of Heidelberg.
  </p>\n            </td>\n        </tr>\n    </tbody>\n</table>\n<p>&nbsp\
 ;</p>
END:VEVENT
END:VCALENDAR